The viral story of an Australian tech entrepreneur using ChatGPT, Grok, and other AI tools to craft a personalized cancer vaccine for his dog has reached its commercial evolution. Paul Conyngham has officially launched Gamgee, a startup dedicated to offering “personalised mRNA cancer vaccines for dogs” at scale.
The Promise and the Skepticism
At the heart of Gamgee’s narrative is Rosie, Conyngham’s dog, whose tumors reportedly shrank after receiving a vaccine designed via ChatGPT and computational genomics. Conyngham, who explicitly states on his website that he is “not a biologist,” credits this intervention with extending Rosie's life. However, scientific experts have raised concerns. Previous reporting indicates that the role of AI in Rosie's treatment was unclear and that the vaccine was administered alongside another therapy, making it scientifically impossible to isolate the vaccine's impact.
Furthermore, researchers suggest that the narrative may overstate the capabilities of AI while minimizing the essential contributions of the human scientists involved in the process.
Clinical Trials and Global Ambitions
Despite the scientific ambiguity, Gamgee has secured backing from the prestigious tech incubator Y Combinator. The startup is currently recruiting for its first clinical trials in Australia, collaborating with the University of Queensland and institutes at the University of New South Wales.
- Gamgee claims a roughly 75% tumor reduction in its first documented case.
- The company promises a turnaround time of approximately four weeks for a finished vaccine.
- Beyond pets, the company’s website indicates ambitions to develop personalized treatments for humans.
While the company is currently accepting cases globally through a waitlist, the specific costs for these personalized treatments have not yet been disclosed on the startup's platform.
